CFRXZ
is the stock ticker symbol for ContraFect Corporation's Series 2
warrants. ContraFect Corporation is a clinical-stage biotechnology
company that focuses on the discovery and development of novel protein
and antibody therapeutics for the treatment of life-threatening
bacterial infections.
As of September 2021, ContraFect's lead
product candidate is exebacase, which is a recombinant protein that
targets and destroys certain types of bacteria, including
methicillin-resistant Staphylococcus aureus (MRSA). Exebacase has
completed Phase 2 clinical trials for the treatment of MRSA
bacteremia, and the company is currently conducting Phase 3 clinical
trials for this indication.
ContraFect's pipeline also includes
a range of other product candidates that are in various stages of
development, including CF-370, which is a potent lysin that targets
Streptococcus pneumoniae, and CF-405, which is a potent lysin that
targets Pseudomonas aeruginosa.
As a clinical-stage
biotechnology company, ContraFect's success will depend on its ability
to successfully develop and commercialize its product candidates,
which can be a long and uncertain process. The company also faces
competition from other companies that are developing treatments for
bacterial infections.
Investors who are considering investing
in ContraFect should carefully evaluate the company's financial
position, its product pipeline, and the competitive landscape.
Additionally, investing in clinical-stage biotechnology companies like
ContraFect can be highly risky, and investors should be prepared for
the possibility of significant volatility and potent
|
